This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA

Laura Sepp-Lorenzino, PhD
Biotech Executive, Board Member and Industry Advisor at GNMmeds LLC
Speaker

Profile

Laura Sepp-Lorenzino, Ph.D., is a biotechnology executive and board director with deep expertise in genomic medicine and nucleic acid therapeutics. She is Principal of GNMmeds LLC, advising on genomic medicine R&D and strategy. Laura serves on the boards of Taysha Gene Therapies, AskBio, URSA Medicines, OTS, and ASGCT. Previously, she was Chief Scientific Officer at Intellia Therapeutics (2019–2025), where she helped establish the first clinical proof of in vivo genome editing and advanced multiple programs into pivotal trials. Earlier, she held senior leadership roles at Vertex, Alnylam, and Merck, following foundational research training at Memorial Sloan-Kettering. She earned her degrees in biochemistry from the University of Buenos Aires and New York University.

Agenda Sessions

  • From Sequence to Therapy: Innovations in Oligonucleotide and Genome Editing Medicines

    1:45pm